EnglishУкраїнська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    Moroz L.V., Androsova O.S., Davyduk I.A.

    FUNCTIONAL CHANGES IN LIVER CONDITION AT PATIENTS WITH ACQUIRED HUMAN IMMUNODEFICIENCY SYNDROME


    About the author: Moroz L.V., Androsova O.S., Davyduk I.A.
    Heading GASTROENTEROLOGY AND HEPATOLOGY
    Type of article Научная статья
    Annotation The correlation between reciving highly active antiretroviral therapies and development hepatotoxicity were studied at 75 patients with AIDS. Different levels of hepatotoxicity were registered in all patients. But in patients with coinfection HIV/HCV were developed more severe hepatotoxicity than patients with monoinfection HIV (hepatotoxicity of 3, 4 levels were registered in 6 times more often, than at patients with HIV monoinfection).
    Tags Acquired Immunodeficiency Syndrome, highly active antiretroviral therapy, hepatotoxicity.
    Bibliography
    • Гепатотоксичность у больных ВИЧ-инфекцией, получавших высокоактивную антиретровирусную терапию / В.Г. Канестри, А.В. Кравченко, Н.Ю. Ганкина, А.В. Мирошниченко // Эпидемиология и инфекционные болезни. – 2006. - №6. – С. 31-34.
    • Колесникова Е.В. Особенности поражения печени при ВИЧ-инфекции / Е.В. Колесникова // Сучасна гастроентерологія. – 2008. – №5. – С. 100-104.
    • Dieterich D. Drug-indused liver injury assotiated with the use of nonnucleoside reverse-transcriptase inhibitors / Douglas T. Dieterich, Patrick A. Robinson, J. Love // Clinical Infectious Diseases. – 2004. – Vol.38, Suppl.2. – P. 80-90.
    • Kontoris N. Hepatotoxicity of Antiretroviral Therapy / N. Kontoris, D. Dieterich // AIDS Reviews. – 2003. – Vol.5. – P. 36-43.
    • Langohr K. Liver enzyme alterations in HCV – Monoinfected and HCV/HIV – Coinfected patients / Langohr K., Sanvisens A., Fuster D. // The Open AIDS Journal. – 2008. – Vol.2. – P. 82-88.
    • Maida I. Sever Liver Diseases Associated With Prolonged Exposure to Antiretroviral Drugs / Maida I., Nunez M., Rios M.J. // J Acquir Immune Defic Syndr. – 2006. – Vol.42. – P. 177-182.
    • Martin-Carbonero L. Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine / L. Martin-Carbonero, M. Nunez, J. Gonzalez-Lahoz // HIV Clinical Trials. – 2003. – Vol.4. – P. 115-120.
    • Montessori V. Adverse effects of antiretroviral therapy for HIV infection / V. Montessori, N. Press, M. Harris // CMAJ. – 2004. – Vol.20. – P. 229-238.
    • Nunez M. Hepatotoxicity of antiretrovirals; Incidence, mechanisms and management / M. Nunez // Journal of Hepatology. – 2006. – Vol.44. – P. 132-139.
    • Cohen S. The spread, treatment, and prevention of HIV-1: evolution of global pandemic / Myron S. Cohen, N. Hellmann, Jay A. Levy // The Journal of Clinical Investigation. – 2008. – Vol.118. – P. 1244-1254.
    • Rivero A. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors / A. Rivero, J. A. Mira, J. A. Pineda // Journal of Antimicrobial Chemotherapy. – 2007. – Vol.59. – P. 342-346.
    • Torti C. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOCA-MASTER Cohort / C. Torti, G. Lapadula, S. Casari // BMC Infectious Diseases. – 2005. – Vol.5. – P. 58-68.
    • Walensky P. The survival benefits of AIDS treatment in the United States/ P. Walensky, D. Paltiel, E. Losina // The Journal of Infectious Diseases. – 2006.– 194(1). – P. 11-19.
    • Walensky P. When to start antiretroviral therapy in resourse – limited settings / P. Walensky, L. Wolf, R. Wood // Annals of Internal Medicine. – 2009. – (1). – P. 157-166.
    Publication of the article «World of Medicine and Biology» №2(25), 2010 year, 131-134 pages, index UDK 611-018.5:616